Cyclophosphamide vs. Infliximab for Refractory Idiopathic Scleritis (CIRIS)

NCT03088293 · clinicaltrials.gov ↗

PHASE3

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped recruiting difficulties

Conditions

Idiopathic Refractory Scleritis

Interventions

DRUG: Infliximab
DRUG: Cyclophosphamide

Sponsor

Hospices Civils de Lyon